Latest From Acusphere Inc.
This week’s roundup includes CEO appointments by Smart Matrix and IRX Therapeutics, with various senior level appointments by companies including Therachon, Mission Therapeutics and bluebird bio.
Chiasma, a US privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, has appointed Mark Leuchtenberger president and CEO. Mr Leuchtenberger brings 25 years of industry experience to Chiasma, including CEO positions with Acusphere, Rib-X Pharmaceuticals, Targanta Therapeutics and Therion Biologics. From 1996 to 2002, he held multiple senior positions with Biogen, where he managed North American and international commercial operations. He currently serves as advisory board chair of the Massachusetts Emerging Technology Fund, MassDevelopment, and as a trustee and member of the Medical Education Committee, Beth Israel Deaconess Medical Center. And is also a board member of the Massachusetts Biotechnology Council.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
- Controlled Release
- Radiopharmaceuticals, Contrast Agents
- Drug Delivery
- Therapeutic Areas
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
- Acusphere Inc.
- Senior Management
Mark Leuchtenberger, Pres. & CEO
William Ramage, DPhil, Chief Dev. Officer
- Contact Info
Phone: (617) 648-8800
500 Arsenal St.
Watertown, MA 02472
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.